Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
repeated dose toxicity: oral, other
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1953
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
data from handbook or collection of data
Remarks:
WHO report

Data source

Reference
Reference Type:
review article or handbook
Title:
Unnamed
Year:
2006
Report date:
2006

Materials and methods

Test guideline
Qualifier:
no guideline followed
Principles of method if other than guideline:
Kaiser, K. (1953) Investigations on the carcinogenic activity of indole in rats. Zeitschrift Krebsforschung, 59, 488–495.
GLP compliance:
no

Test material

1
Chemical structure
Reference substance name:
Indole
EC Number:
204-420-7
EC Name:
Indole
Cas Number:
120-72-9
Molecular formula:
C8H7N
IUPAC Name:
1H-indole
Test material form:
solid

Test animals

Species:
rat
Strain:
other: Strain W
Details on species / strain selection:
Groups of five male and twenty female strain W rats were maintained on a diet providing indole at a dose of 0 or 100 mg/kg bw per day for 460 days, followed by a 30-day period of no treatment to examine the possible reversibility of any
treatment-related effects.
Sex:
male/female
Details on test animals or test system and environmental conditions:
Groups of five male and twenty female strain W rats were maintained on a diet providing indole at a dose of 0 or 100 mg/kg bw per day for 460 days, followed by a 30-day period of no treatment to examine the possible reversibility of any
treatment-related effects.

Administration / exposure

Route of administration:
oral: feed
Duration of treatment / exposure:
Groups of five male and twenty female strain W rats were maintained on a diet providing indole at a dose of 0 or 100 mg/kg bw per day for 460 days, followed by a 30-day period of no treatment to examine the possible reversibility of any
treatment-related effects. Following the reversibility period, treatment with a diet providing indole at a dose of 200 mg/kg bw per day was continued for 100 additional days.
Doses / concentrationsopen allclose all
Dose / conc.:
100 mg/kg bw (total dose)
Dose / conc.:
0 mg/kg bw (total dose)
Dose / conc.:
200 mg/kg bw (total dose)
No. of animals per sex per dose:
Groups of five male and twenty female strain W rats were maintained on a diet
Control animals:
yes

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Animals were monitored every 2 weeks for food consumption, body weight,
survival and haematological effects. At necropsy, liver, kidney, and spleen were examined microscopically. Rats maintained on a diet supplemented with indole showed a 20% reduction in body-weight gain compared with controls. The
haematological profile obtained for the first 460 days revealed slightly reduced concentrations of haemoglobin and erythrocyte counts compared with thoseof the controls (i.e. haemoglobin, 15.2 versus 13.8 g Hb/100 ml blood; and erythrocyte count, 8 versus 6.4 million cells/ml blood, respectively), which were reversible upon cessation of treatment. By day 460, the leukocyte counts reached twice their
original values, which the authors stated were still within the normal range of values for rats. No leukaemia or other tumours attributable to administration of indole were observed in the animals. The average life expectancy of the rats was not altered by the inclusion of indole in the diet. Except for indications of moderate reversible anaemia, no other adverse effects were reported (Kaiser, 1953).
Mortality:
no mortality observed
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
Animals were monitored every 2 weeks for food consumption, body weight,
survival and haematological effects. At necropsy, liver, kidney, and spleen were examined microscopically. Rats maintained on a diet supplemented with indole showed a 20% reduction in body-weight gain compared with controls.
Haematological findings:
effects observed, treatment-related
Description (incidence and severity):
Animals were monitored every 2 weeks for food consumption, body weight,
survival and haematological effects. At necropsy, liver, kidney, and spleen were examined microscopically. Rats maintained on a diet supplemented with indole showed a 20% reduction in body-weight gain compared with controls. The
haematological profile obtained for the first 460 days revealed slightly reduced concentrations of haemoglobin and erythrocyte counts compared with thoseof the controls (i.e. haemoglobin, 15.2 versus 13.8 g Hb/100 ml blood; and erythrocyte count, 8 versus 6.4 million cells/ml blood, respectively), which were reversible upon cessation of treatment. By day 460, the leukocyte counts reached twice their
original values, which the authors stated were still within the normal range of values for rats. No leukaemia or other tumours attributable to administration of indole were observed in the animals. The average life expectancy of the rats was not altered by the inclusion of indole in the diet. Except for indications of moderate reversible anaemia, no other adverse effects were reported (Kaiser, 1953).

Effect levels

Key result
Dose descriptor:
NOEL
Effect level:
< 100 mg/kg bw (total dose)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
body weight and weight gain
haematology
mortality
Remarks on result:
not determinable due to adverse toxic effects at highest dose / concentration tested

Target system / organ toxicity

Key result
Critical effects observed:
yes
Lowest effective dose / conc.:
100 mg/kg bw (total dose)
System:
haematopoietic
Organ:
kidney
liver
spleen
Treatment related:
yes
Dose response relationship:
yes
Relevant for humans:
not specified

Applicant's summary and conclusion

Conclusions:
590 days NOEL is l < 100 mg/kg bw/day determined by WHO report. .
Executive summary:

Groups of five male and twenty female strain W rats were maintained on a diet providing indole at a dose of 0 or 100 mg/kg bw per day for 460 days, followed by a 30-day period of no treatment to examine the possible reversibility of any

 treatment-related effects. Following the reversibility period, treatment with a diet providing indole at a dose of 200 mg/kg bw per day was continued for 100 additional days. A concurrent control group was maintained, but was not described.

 Animals were monitored every 2 weeks for food consumption, body weight,

 survival and haematological effects. At necropsy, liver, kidney, and spleen were examined microscopically. Rats maintained on a diet supplemented with indole showed a 20% reduction in body-weight gain compared with controls. The

 haematological profile obtained for the first 460 days revealed slightly reduced concentrations of haemoglobin and erythrocyte counts compared with thoseof the controls (i.e. haemoglobin, 15.2 versus 13.8 g Hb/100 ml blood; and erythrocyte count, 8 versus 6.4 million cells/ml blood, respectively), which were reversible upon cessation of treatment. By day 460, the leukocyte counts reached twice their

 original values, which the authors stated were still within the normal range of values for rats. No leukaemia or other tumours attributable to administration of indole were observed in the animals. The average life expectancy of the rats was not altered by the inclusion of indole in the diet. Except for indications of moderate reversible anaemia, no other adverse effects were reported (Kaiser, 1953).